Abstract
Anti cancer agent 5-FU (Fluoro Uracil) is a prodrug that can be metabolized and then activated to interfere with RNA and DNA homeostasis. However, the majority of administered 5-FU is known to be catabolized in vivo in the liver where Dihydropyrimidine dehydrogenase (DPD) is abundantly expressed to degrade 5-FU. The biological factors that correlate with the response to 5-FU-based chemotherapy have been proposed to include uridine phosphorylase (UPP), thymidine phosphorylase (TPP), p53 and microsatellite instability. Among these, the expression of UPP is known to be controlled by cytokines such as TNF-α, IL1 and IFN-γ. Our preliminary study using a DNA microarray technique showed that basic fibroblast growth factor (bFGF) markedly induced the expression of UPP1 at the transcription level. In the present study, we investigated whether bFGF could modulate the expression of UPP1 in osteo-lineage cells and examined the sensitivity of these cells to 5-FU mediated apoptosis.
Similar content being viewed by others
References
Al Safarjalani, O.N., Zhou, X.J., Rais, R.H., Shi, J., Schinazi, R.F., Naguib, F.N., and El Kouni, M.H. (2005). 5-(Phenylthio) acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. Cancer Chemother. Pharmacol. 55, 541–551.
Baynes, J.W., and Dominiczak, M.H. (2005). Medical Biochemistry (Elsevier Mosby), pp.417–423.
Cao, D., and Pizzorno, G. (2004). Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today (Barc.) 40, 431–443.
Diasio, R.B., and Harris, B.E. (1989). Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16, 215–237.
Douillard, J.Y., Cunningham, D., Roth, A.D., Navarro, M., James, R.D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041–1047.
el Kouni, M.H., Naguib, F.N., Park, K.S., Cha, S., Darnowski, J.W., and Soong, S.J. (1990). Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. Biochem. Pharmacol. 40, 2479–2485.
Geng, Y., Gheuens, E., and de Bruijn, E.A. (1991). Activation and cytotoxicity of 5′-deoxy-5-fluorouridine in c-H-ras transformed NIH 3T3 cells. Biochem. Pharmacol. 41, 301–303.
Giacchetti, S., Perpoint, B., Zidani, R., Le, B.N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J.F., Letourneau, Y., Coudert, B., et al. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18, 136–147.
Greco, F.A., Figlin, R., York, M., Einhorn, L., Schilsky, R., Marshall, E.M., Buys, S.S., Froimtchuk, M.J., Schuller, J., Schuchter, L., et al. (1996). Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J. Clin. Oncol. 14, 2674–2681.
Johnston, P.G., and Kaye, S. (2001). Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 12, 639–646.
Kim, S., Park, D.H., and Shim, J. (2008). Thymidylate synthase and dihydropyrimidine dehydrogenase levels are associated with response to 5-fluorouracil in Caenorhabditis elegans. Mol. Cells 16, 344–349.
Lee, S.J., Lee, H.K., Cho, S.Y., Choi, J.K., Shin, H.K., Kwak, E.J., Cho, M.R., Kim, H.R., Kim, S.R., Kim, Y.M., et al. (2008). Identification of osteogenic purmorphamine deriva-tives. Mol. Cells 26, 380–386.
Longley, D.B., Harkin, D.P., and Johnston, P.G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330–338.
Moyer, J.D., Oliver, J.T., and Handschumacher, R.E. (1981). Salvage of circulating pyrimidine nucleosides in the rat. Cancer Res. 41, 3010–3017.
Schwartz, E.L., Wan, E., Wang, F.S., and Baptiste, N. (1998). Regulation of expression of thymidine phosphorylase/plateletderived endothelial cell growth factor in human colon carcinoma cells. Cancer Res. 58, 1551–1557.
Seymour, M.T., Slevin, M.L., Kerr, D.J., Cunningham, D., James, R.D., Ledermann, J.A., Perren, T.J., McAdam, W.A., Harper, P.G., Neoptolemos, J.P., et al. (1996). Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J. Clin. Oncol. 14, 2280–2288.
Voboril, R., Hochwald, S.N., Li, J., Brank, A., Weberova, J., Wessels, F., Moldawer, L.L., Camp, E.R., and MacKay, S.L. (2004). Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J. Surg. Res. 120, 178–188.
Wan, L., Cao, D., Zeng, J., Yan, R., and Pizzorno, G. (2006). Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5′-deoxy-5-fluorouridine in breast cancer cells. Mol. Pharmacol. 69, 1389–1395.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Im, YS., Shin, H.K., Kim, HR. et al. Enhanced cytotoxicity of 5-FU by bFGF through up-regulation of uridine phosphorylase 1. Mol Cells 28, 119–124 (2009). https://doi.org/10.1007/s10059-009-0116-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10059-009-0116-x